meiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 42642427 |
| CHEMBL ID | 556082 |
| CHEMBL ID | 3339153 |
| MeSH ID | M0545696 |
| Synonym |
|---|
| meiogynin a |
| CHEMBL556082 , |
| bdbm50295162 |
| CHEMBL3339153 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| BH3-interacting domain death agonist | Homo sapiens (human) | Ki | 8.4333 | 0.2000 | 4.2000 | 8.6000 | AID1166894; AID1635029 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Ki | 15.6000 | 0.0000 | 0.4581 | 9.0000 | AID1166893; AID1635028; AID421902 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | Ki | 8.4333 | 0.0010 | 1.4653 | 9.5400 | AID1166894; AID1635029 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | Ki | 17.2000 | 0.0010 | 2.7182 | 9.0000 | AID1166893; AID1635028 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1166893 | Inhibition of Bcl-xL/Bak (unknown origin) interaction | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. |
| AID1635028 | Inhibition of His-tagged Bcl-xL/5-carboxyfluorescein-Bak (unknown origin) after 1 hr by fluorescence polarization assay | 2016 | Journal of natural products, Apr-22, Volume: 79, Issue:4 | Anacardic Acids from Knema hookeriana as Modulators of Bcl-xL/Bak and Mcl-1/Bid Interactions. |
| AID421902 | Displacement of fluorescent-tagged BH3 domain of Bak from Bcl-xL by fluorescence polarization assay | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction. |
| AID1166894 | Inhibition of Mcl1/Bid (unknown origin) interaction | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. |
| AID1635029 | Inhibition of His-tagged Mcl-1/5-carboxyfluorescein-Bid (unknown origin) after 1 hr by fluorescence polarization assay | 2016 | Journal of natural products, Apr-22, Volume: 79, Issue:4 | Anacardic Acids from Knema hookeriana as Modulators of Bcl-xL/Bak and Mcl-1/Bid Interactions. |
| AID421903 | Cytotoxicity against human KB cells | 2009 | Journal of natural products, Mar-27, Volume: 72, Issue:3 | A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction. |
| AID1166898 | Cytotoxicity against BL2 cells (unknown origin) assessed as cell killing after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. |
| AID1166899 | Cytotoxicity against BL2/B95 cells (unknown origin) assessed as cell killing after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. |
| AID1166900 | Cytotoxicity against Remb1 cells (unknown origin) assessed as cell killing after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.75) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||